Long-Acting Injectable Antipsychotic Medications in an Aging Population-Presentation Slides

Presentation Slides

Pdf Summary

This document is a summary of a presentation on the use of long-acting injectable antipsychotic medications in an aging population. The presentation was part of the Clinical Support System for Serious Mental Illness (CSS-SMI), which is funded by the Substance Abuse and Mental Health Services Administration (SAMHSA) and implemented by the American Psychiatric Association (APA).<br /><br />The presentation discusses the increased risk of psychosis in the elderly, as well as the age-related changes in the brain and body that can contribute to these symptoms. It covers the different types of primary and secondary disorders that can cause psychosis in the elderly, and the need for a careful evaluation of the possible causes before initiating treatment.<br /><br />The presentation discusses the use of antipsychotic medications, both short-term and long-term, in the treatment of psychosis in the elderly. It highlights the importance of considering the individual's physical condition, comorbid medical disorders, and cognitive abilities when determining the appropriate dose and administration plan.<br /><br />The presentation also discusses the challenges of medication adherence in the elderly population, as well as the age-related changes in pharmacokinetics and pharmacodynamics that can affect the efficacy and side effects of antipsychotic medications.<br /><br />The use of long-acting injectable antipsychotic medications is explored as a treatment option for the elderly population, including the benefits of stable plasma concentration and regular contact with healthcare providers. The presentation also addresses the potential adverse effects of these medications, such as postural hypotension, sedation, anticholinergic effects, and motor effects. <br /><br />The presentation includes information on the administration of different long-acting injectable antipsychotic medications, including injection volumes and sites. It emphasizes the importance of accurate injection technique and individualized dosing based on body type and characteristics.<br /><br />In summary, the presentation highlights the considerations and challenges in the use of long-acting injectable antipsychotic medications in an aging population, and provides recommendations for evaluation, management, and administration in this population.

Keywords

long-acting injectable antipsychotic medications

aging population

Clinical Support System for Serious Mental Illness

Substance Abuse and Mental Health Services Administration

American Psychiatric Association

psychosis in the elderly

age-related changes

primary and secondary disorders

medication adherence

pharmacokinetics and pharmacodynamics